SIGA Technologies Inc. - Common Stock (SIGA)

Siga Technologies (NASDAQ:SIGA) reported second-quarter product-related revenue of $38 million, driven primarily by deliveries of intravenous TPOXX to the U.S. Strategic National Stockpile and oral TPOXX sales to international customers. The company said the quarter reflected the variable timing of

Siga Technologies (NASDAQ:SIGA) reported a first-quarter loss as product deliveries remained minimal, but management said it expects a pickup in the second quarter tied to an international order and additional deliveries to the U.S. Strategic National Stockpile. Chief Executive Officer Diem Nguyen

SIGA (SIGA) Q1 2026 Earnings Call Transcript

SIGA Technologies’ (NASDAQ:SIGA) antiviral drug tecovirimat, when used without other treatments, did not reduce the time for clade ...

SIGA Technologies Inc. (NASDAQ: SIGA) shares are trading higher Friday after the company declared a special cash dividend of $0.60 per share.

Income investors seeking juicy dividends should check out these healthcare stocks.

Several stocks ranging from mega-cap to small-cap just announced notable increases to their dividends. One of these names is among the three largest stocks in the software industry.

The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Japan approves SIGA's TEPOXX for smallpox, mpox, and cowpox, expanding antiviral availability for orthopoxviruses with proven safety and efficacy.

Shares of Rumble Inc.

To fight the mpox outbreak in Africa, the World Health Organization calls for funding help for its six-month plan.

SIGA Technologies secures a $9 million DoD contract for TPOXX, boosting total outstanding orders to $154 million. Recent BARDA and DoD wins reinforce growth despite challenges in a key mpox trial.

Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.

The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.

Mpox rerun is making these stocks soar. But a non-vaccine approach could yield greater gains.

Increased screening for deadly new version of mpox is seen in Europe and China. More imported cases are expected. New vaccines are being developed.

Shares of SIGA Technologies (SIGA) had a 'bull trap' on Wednesday. There may be another one today. This can mean the stock is headed lower.